Drugs / Dalantercept
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00996957 | Oct 2009 → Jun 2012 | plasma cell myeloma | Acceleron Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02024087 | Aug 2014 → Jul 2017 | adult hepatocellular carcinoma | Acceleron Pharma, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01727336 | Dec 2012 → Jun 2017 | renal cell carcinoma | Acceleron Pharma, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01720173 | Nov 2012 → Oct 2015 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01642082 | Sep 2012 → Jan 2016 | endometrial clear cell adenocarcinoma, endometrial mixed adenocarcinoma, endometrial mucinous adenocarcinoma, endometrial serous adenocarcinoma +3 | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT01458392 | Oct 2011 → Jun 2015 | head and neck squamous cell carcinoma | Acceleron Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dalantercept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02024087 ↗ |
| Known as | ACE-041 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00996957 ↗ |
| Known as | NSC #757172 | “A Phase II Evaluation of Dalantercept (NSC #757172), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of...” NCT01720173 ↗ |
| Action | Inhibit | “Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor” NCT01642082 ↗2“Growth/differentiation factor 2 inhibitor” CHEMBL2109662 ↗ “Bone morphogenetic protein 10 inhibitor” CHEMBL2109662 ↗ |
| Modality | Protein / enzyme biologic | “a soluble form of the activin receptor-like kinase-1 protein” NCT01458392 ↗ |
| Route | Subcutaneous | “Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses.” NCT00996957 ↗ |
| Target | ACVRL1 | “Targeting the activin receptor-like kinase 1 (ALK1)” PMID 30352941 ↗ Oct 2018 |
| Target | BMP10 | “Bone morphogenetic protein 10 inhibitor” CHEMBL2109662 ↗ |
| Target | GDF2 | “Growth/differentiation factor 2 inhibitor” CHEMBL2109662 ↗ |